Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase Ia/Ib Dose-escalation and Dose-expansion Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of SCTB35 in Patients With CD20+ Relapse/Refractory B-cell Non-Hodgkin Lymphoma

NCT06318884 is registered in ClinicalTrials.gov with Sinocelltech Ltd. as lead sponsor.

NCT NCT06318884
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06318884 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase Ia/Ib Dose-escalation and Dose-expansion Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of SCTB35 in Patients With CD20+ Relapse/Refractory B-cell Non-Hodgkin Lymphoma
Lead sponsor
Sinocelltech Ltd.
Phase
Phase 1
Overall status
Not yet recruiting
Start date
April 30, 2024
Completion date
December 31, 2027
Enrollment
76 (estimated)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

non-hodgkin lymphoma, b-cell